Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Woodcock's 'Bias' In Sarepta Case Made Jenkins Worry About Future Drug Reviews

Aug 01 2017

• By Derrick Gingery

Related Content

Jenkins’ Exit Interview: He’ll Miss Insider Status Upon FDA Departure

Dec 13 2016

Patient Advocacy With FDA Review Staff Will Be Tougher Post-Sarepta

Sep 23 2016

Woodcock's Consideration of Sarepta Financial Issues Raises Eyebrows

Sep 20 2016

Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate

Sep 20 2016

Woodcock's Legacy: CDER Organizational Improvements

Aug 10 2016

Sarepta’s Aftermath: FDA Staff Still Working Together, Califf Says

Nov 16 2016

No More Sarepta-Like Development, FDA Officials Say

Oct 20 2016

Duchenne Muscular Dystrophy: Second Product Isn't The Charm

Jan 15 2016

CDER Director Woodcock Plans Changes To Drug Reviews During OND Transition

Mar 07 2017

Related Companies

Sarepta Therapeutics, Inc.

Additional Topics

United States Drug Review FDA Leadership BioPharmaceutical

More from Product Reviews

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window